ENGLISH · RESEARCH LIBRARY
Each entry shows the molecule's pharmacology, regulatory class, evidence grade and a concise English evidence boundary.
Class describes development/regulatory context; grade describes evidence strength, not which molecule is better.
Select 2–3 molecules to compare evidence, not treatment recommendations.
EVIDENCE VISUAL · Clinical / Endocrine PharmacologyCardiogen has preclinical myocardial-explant and animal data. Proliferation and p53 changes do not establish improved human cardiac function or survival. Supplier sequence, formulation and authorisation are unverified. It is not a substitute for evidence-based cardiac care.
EVIDENCE VISUAL · Clinical / Endocrine PharmacologyVesugen is KED, not KEDG or KEDW. Endothelial-cell, fibroblast and docking findings concern proliferation/differentiation markers. They do not establish prevention of stroke or heart attack, and human-derived cells are not human clinical trials.
EVIDENCE VISUAL · Clinical / Endocrine PharmacologyThe 2022 THP-1 study identifies Chonluten as EDG. Its cell-signalling and TNF findings do not establish treatment of asthma, COPD or lung injury. Chonluten must not inherit evidence from Bronchogen or different vendor sequences.
EVIDENCE VISUAL · Clinical / Endocrine PharmacologyPancragen is KEDW, with terminal-form details requiring verification. A limited report included 30 healthy older adults and 33 people with type 2 diabetes; its abstract does not establish a randomised 63-person treatment trial. Biomarker and cell-differentiation findings do not justify replacing insulin or standard diabetes care.
EVIDENCE VISUAL · Clinical / Endocrine PharmacologyEPO is an erythropoietic hormone and an ambiguous catalogue label, not a verified product identity. Authorised epoetin medicines treat selected anaemias, with risks including hypertension and thrombosis. Specific ESA warnings include stroke, cardiovascular events and tumour progression in defined settings. No endurance-enhancement recommendation is made.
EVIDENCE VISUAL · Clinical / Endocrine PharmacologyInsulin medicines are essential in defined diabetes settings but can cause life-threatening hypoglycaemia. Human insulin, analogues and premixes differ. A catalogue entry without the exact type, formulation and device cannot identify an authorised medicine or support product switching or bodybuilding use.
EVIDENCE VISUAL · Clinical / Endocrine PharmacologyOvagen is linked to the Glu-Asp-Leu (EDL) tripeptide in research-group literature, but that name does not authenticate a supplier product. It must be distinguished from the unrelated ovine FSH preparation also called Ovagen. Verified EDL studies concern renal cell/tissue cultures, rat kidney-injury models and computational DNA docking. Cell biomarkers and animal kidney signals do not establish human liver repair, kidney treatment, anti-aging benefit or administration safety. No randomised human trial of exact EDL was verified in the reviewed sources. Class E denotes unresolved exact-product identity and authorisation; Grade E denotes preclinical evidence. Registration in Thailand, the U.S., EU and UK remains unverified for the supplier product.
EVIDENCE VISUAL · Clinical / Endocrine PharmacologyTestosterone is an endogenous androgen and an active ingredient in authorised prescription medicines, but 'Test' does not identify an ester, formulation, strength, manufacturer or authorisation. Cypionate, enanthate, undecanoate, propionate, no-ester formulations and blends are not automatically interchangeable. TRAVERSE found MACE noninferiority for a specific gel in a defined population while other safety signals remained. This evidence does not authenticate catalogue products or support performance use. WADA 2026 prohibits testosterone and its esters at all times.
EVIDENCE VISUAL · Clinical / Endocrine PharmacologyOstarine, enobosarm, GTx-024 and MK-2866 refer to the same investigational SARM candidate in the reviewed literature. Controlled trials reported lean-body-mass signals in selected older adults and cancer populations, but do not establish bodybuilding benefit, long-term safety or product approval. FDA states that no SARM is approved and warns of serious harms. Online naming does not establish identity or amount, and WADA 2026 prohibits enobosarm at all times.
EVIDENCE VISUAL · Clinical / Endocrine PharmacologyLigandrol and LGD-4033 identify an investigational nonsteroidal SARM candidate. A 21-day placebo-controlled study in 76 healthy men found an exposure-related lean-mass signal alongside suppression of total testosterone, SHBG and HDL. The study was too small and short to establish clinical or bodybuilding benefit or long-term safety. FDA identifies marketed LGD-4033 products as unapproved drugs, and WADA 2026 prohibits ligandrol at all times.
EVIDENCE VISUAL · Clinical / Endocrine PharmacologyRAD140, vosilasarm and the online term Testolone refer to an investigational SARM candidate; Testolone is not testosterone. A first-in-human study enrolled 22 postmenopausal women with advanced breast cancer and reported target engagement, preliminary antitumour activity and frequent liver-test abnormalities. This does not establish bodybuilding or performance benefit, safety in healthy users or approval. FDA identifies marketed RAD-140 products as unapproved drugs, and WADA prohibits RAD140 at all times.
EVIDENCE VISUAL · Clinical / Endocrine PharmacologyAndarine, S4 and GTx-007 identify an experimental nonsteroidal SARM in the reviewed sources. Evidence is dominated by rat muscle, bone and reproductive-tissue models; these signals do not establish human treatment, performance benefit or long-term safety. FDA records identify marketed andarine products as unapproved drugs and document a product recall involving andarine and ostarine. WADA 2026 prohibits andarine at all times.
Showing 12 of 62 profiles
EDUCATIONAL DILUENT GUIDE
Understand bacteriostatic water, preservative-free sterile water, single-dose/multiple-dose labels and key DailyMed/FDA warnings—without preparation or administration instructions.
ANDROGEN EVIDENCE GUIDE
Separate testosterone from esters, blends, Testagen and supplier terms, with TRAVERSE, FDA labeling, safety and WADA context—without doses or administration protocols.
ANABOLIC STEROIDS EVIDENCE MAP
Classify testosterone, nandrolone, trenbolone, DHT-derived and boldenone agents while separating HGH, SARMs, clenbuterol and hormone-modifying medicines—without cycles, doses or injection protocols.
SARM EVIDENCE GUIDE
Review ostarine, ligandrol, RAD140, andarine and YK-11 while separating commonly misclassified MK-677, cardarine and SR9009, with FDA and WADA boundaries.
IDENTITY NOTICES · NOT EVIDENCE PROFILES
These notices are public, but the exact products remain unidentified. They are separate from Evidence Profiles and excluded from their counts, rankings and comparison filters.
The name FOXO4 does not establish whether this item is the FOXO4 protein, a FOXO4-DRI peptide or another material. This page documents an unresolved identity, not a verified senolytic or anti-aging product.
COCK BOMBS is a product name with no verified ingredient information. The name alone does not identify an active molecule. This page assigns no formula, benefit or drug class.
Pure water does not specify grade, sterility, preservatives or an authorised purpose. It is not established as Sterile Water for Injection or Bacteriostatic Water.
Cagrilintide + semaglutide blend remains an unverified catalogue product. The supplier document claims cagrilintide and semaglutide, but that is not proof of composition, quality, safety or authorisation.
Retatrutide + cagrilintide blend remains an unverified catalogue product. The supplier document claims retatrutide and cagrilintide, but that is not proof of composition, quality, safety or authorisation.
Ipamorelin + tesamorelin blend remains an unverified catalogue product. The supplier document claims ipamorelin and tesamorelin, but that is not proof of composition, quality, safety or authorisation.
BPC-157 + TB-500 blend remains an unverified catalogue product. The supplier document claims BPC-157 and TB-500, but that is not proof of composition, quality, safety or authorisation.
CJC-related peptide + ipamorelin blend remains an unverified catalogue product. The supplier document claims a CJC-related peptide and ipamorelin, but that is not proof of composition, quality, safety or authorisation.
GHK-Cu + TB-500 + BPC-157 blend remains an unverified catalogue product. The supplier document claims GHK-Cu, TB-500 and BPC-157, but that is not proof of composition, quality, safety or authorisation.
BPC-157 + GHK-Cu + TB-500 + KPV blend remains an unverified catalogue product. The supplier document claims BPC-157, GHK-Cu, TB-500 and KPV, but that is not proof of composition, quality, safety or authorisation.
Acetic acid water 0.6% remains an unverified catalogue product. The supplier document claims water with an acetic-acid concentration claim, but that is not proof of composition, quality, safety or authorisation.
Lipo-C (LC120) remains an unverified catalogue product. The supplier document claims methionine, choline, carnitine and dexpanthenol, but that is not proof of composition, quality, safety or authorisation.
Lemon Bottle remains an unverified catalogue product. The supplier document claims a trade name without a reliable ingredient identity in the supplied document, but that is not proof of composition, quality, safety or authorisation.
LC216 blend remains an unverified catalogue product. The supplier document claims amino acids, methionine, inositol, choline and B vitamins, but that is not proof of composition, quality, safety or authorisation.
Lipo-C FAT BLASTER remains an unverified catalogue product. The supplier document claims carnitine, methionine, inositol, choline, vitamins and NADH, but that is not proof of composition, quality, safety or authorisation.
SUPER SHRED remains an unverified catalogue product. The supplier document claims carnitine, MIC blend, ATP, albuterol and vitamin B12, but that is not proof of composition, quality, safety or authorisation.
SUPER Human Blend remains an unverified catalogue product. The supplier document claims multiple amino acids, carnitine and NAC, but that is not proof of composition, quality, safety or authorisation.
Healthy Hair Skin Nails Blend remains an unverified catalogue product. The supplier document claims multiple B vitamins, choline, inositol, biotin and folic acid, but that is not proof of composition, quality, safety or authorisation.
Lipo-C FOCUS remains an unverified catalogue product. The supplier document claims ATP, Eria jarensis, carnitine, MIC blend, lidocaine and benzyl alcohol, but that is not proof of composition, quality, safety or authorisation.
Relaxation PM remains an unverified catalogue product. The supplier document claims GABA, melatonin, arginine and glutamine, but that is not proof of composition, quality, safety or authorisation.
Lipo Mino Mix remains an unverified catalogue product. The supplier document claims B vitamins, methionine, inositol, choline and carnitine, but that is not proof of composition, quality, safety or authorisation.
Immunological enhancement blend remains an unverified catalogue product. The supplier document claims glutathione, ascorbic acid and zinc sulfate, but that is not proof of composition, quality, safety or authorisation.
SHRED blend remains an unverified catalogue product. The supplier document claims carnitine, B vitamins, inositol, methionine and choline, but that is not proof of composition, quality, safety or authorisation.
GHK-Cu + glutathione blend remains an unverified catalogue product. The supplier document claims GHK-Cu, glutathione, histidine, glycine and NADH, but that is not proof of composition, quality, safety or authorisation.
Trenbolone acetate + trenbolone enanthate blend remains an unverified catalogue product. The supplier document claims trenbolone acetate and trenbolone enanthate, but that is not proof of composition, quality, safety or authorisation.
Three-ester trenbolone blend remains an unverified catalogue product. The supplier document claims three trenbolone esters, but that is not proof of composition, quality, safety or authorisation.
Trenbolone + drostanolone + testosterone propionate blend remains an unverified catalogue product. The supplier document claims trenbolone acetate, drostanolone propionate and testosterone propionate, but that is not proof of composition, quality, safety or authorisation.
Trenbolone + drostanolone + testosterone enanthate blend remains an unverified catalogue product. The supplier document claims trenbolone enanthate, drostanolone enanthate and testosterone enanthate, but that is not proof of composition, quality, safety or authorisation.
Trenbolone enanthate + drostanolone enanthate blend remains an unverified catalogue product. The supplier document claims trenbolone enanthate and drostanolone enanthate, but that is not proof of composition, quality, safety or authorisation.
Nandrolone phenylpropionate + nandrolone decanoate blend remains an unverified catalogue product. The supplier document claims nandrolone phenylpropionate and nandrolone decanoate, but that is not proof of composition, quality, safety or authorisation.
Drostanolone enanthate + drostanolone propionate blend remains an unverified catalogue product. The supplier document claims drostanolone enanthate and drostanolone propionate, but that is not proof of composition, quality, safety or authorisation.
Ripex-225 remains an unverified catalogue product. The supplier document claims no composition stated in the supplied line, but that is not proof of composition, quality, safety or authorisation.
These pages use noindex while identity remains unresolved. Visitors can still open and read them normally.
The site owner clarified the intended names as SLU-PP-332 (previously SLU-PP-322) and BPC-157 (previously unspecified BPC). These link to existing Evidence Profiles without duplicate entries. This naming correction does not verify supplier-product identity, quality, safety or authorisation.
READER INTEREST · ALL TIME
Most-opened Evidence Profiles and guides, combining Thai and English editions. Reading popularity is not evidence of safety, effectiveness or a recommendation to use a substance.
Loading reading statistics…
Counts page opens, not unique people or completed reads. Reloads may count again. Known bots are excluded where detectable; blocking scripts or cookies may reduce recorded counts. No individual reading history is stored.
IMPORTANT BOUNDARY
They do not provide prices, purchasing, dosing, injection protocols, diagnosis or individual treatment advice. Regulatory status may change and must be checked against current official records.
